Bordeaux

• RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab Recruiting
  2024-514327-42-00 4 2025-12-18 Advanced neuroendocrine carcinomas (NECs) of the digestive system or u
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting
  2025-521293-34-00 4 2025-12-09 Moderate-to-severe hidradenitis suppurativa
• A study comparing nadofaragene firadenovec with standard of care in adults with an increased risk that non-muscle invasive bladder cancer ma … Recruiting
  2024-512029-10-00 5 2025-12-05 Intermediate risk, non-muscle invasive bladder cancer
• A Phase III Randomised, Open Label Trial of an Intradermal or Subcutaneous booster dose of MVA-BN Vaccine to Investigate MPXV Immunogenicity … Recruiting
  2024-518007-22-00 5 2025-12-05 Prevention of monkeypox (mpox) infection
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting
  2025-521040-37-00 5 2025-11-26 HER2-positive early breast cancer
• An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518006-40-00 5 2025-11-13 Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
• A study to assess the effect and safety of efgartigimod IV in participants from 12 years to less than 18 years of age with chronic Immune Th … Recruiting
  2025-521055-23-00 10 2025-10-07 Chronic Idiopathic thrombocytopenic purpura
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
• Clinical study of ruxolitinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with mutations in the IL-7R/JAK-S … Recruiting
  2022-501867-42-01 9 2025-09-08 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• Medical-scientific study of dasatinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with a mutation in the MA … Recruiting
  2022-501866-22-00 9 2025-08-26 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma Recruiting
  2024-516233-12-00 3 2025-08-08 Advanced pancreatic adenocarcinoma
• A Phase 1, Open-Label Dose Escalation and Expansion study of SNV1521 in Participants with Advanced Solid Tumors Recruiting
  2025-520557-36-00 1 2025-07-24 Advanced Solid Tumors
• Phase 2, Multicenter, Open label, Platform Study investigating Tarlatamab (AMG 757) in patients with Metastatic/Locally Advanced Small-Cell … Recruiting
  2024-515847-47-00 4 2025-06-24 Metastaic small cell lung cancer (SCLC) and other poorly differentitat
• BreAK CRC (001) trial Recruiting
  2024-512011-45-00 7 2025-06-17 Unresectable locally advanced or metastatic colorectal cancer
• A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with … Recruiting
  2024-513965-38-01 5 2025-06-16 Sjögren's Disease
• Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting
  2024-517032-22-00 5 2025-06-10 Immune system diseases.
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC) Recruiting
  2024-517819-74-00 9 2025-06-02 Pancreatic Ductal Adenocarcinoma
• A Study to Investigate ALE.P02 as Monotherapy in Adult Patients with Selected CLDN1+ Solid Tumors Recruiting
  2024-515459-39-00 7 2025-05-08 Advanced or Metastatic Squamous Solid Tumors
• A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting
  2024-514459-14-00 4 2025-04-22 Non-Small Cell Lung Cancer
• An Open-Label, Phase 1 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Advanced Solid Tumors, with a Safety Expansion in Advance … Recruiting
  2024-512375-12-00 3 2025-04-18 Solid tumors and ovarian cancer
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting
  2023-508015-23-00 5 2025-04-11 Ovarian cancer recurrent

Showing 121–144 of 1,096 trials